Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • PAVmed's Accumulated Expenses changed N/A to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year change of. This contributed to the annual value of $5.2 million for FY2024, which is 2188.35% down from last year.
  • Per PAVmed's latest filing, its Accumulated Expenses stood at $2.7 million for Q3 2025.
  • PAVmed's Accumulated Expenses' 5-year high stood at $6.8 million during Q2 2024, with a 5-year trough of $1.7 million in Q3 2024.
  • Moreover, its 4-year median value for Accumulated Expenses was $3.7 million (2022), whereas its average is $4.1 million.
  • As far as peak fluctuations go, PAVmed's Accumulated Expenses soared by 8720.14% in 2023, and later plummeted by 6569.03% in 2025.
  • Over the past 4 years, PAVmed's Accumulated Expenses (Quarter) stood at $3.7 million in 2022, then surged by 78.84% to $6.6 million in 2023, then dropped by 21.88% to $5.2 million in 2024, then plummeted by 48.61% to $2.7 million in 2025.
  • Its Accumulated Expenses was $2.7 million in Q3 2025, compared to $2.8 million in Q2 2025 and $2.3 million in Q1 2025.